PVCT OTC
Provectus Biopharmaceuticals, Inc.
1W: -2.7%
1M: -15.1%
3M: -21.7%
YTD: -23.9%
1Y: -33.9%
3Y: -25.3%
5Y: -21.7%
$0.05
-0.00 (-1.31%)
Weekly Expected Move ±7.6%
$0
$0
$0
$0
$0
Credit Risk of going bust: higher than 81% of companies Debt: 14.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 95%), Provectus Biopharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $3.5M against a stock market value of $20.4M.
Distance to default 2.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 80.5%; Altman Z'' -634.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 95%), Provectus Biopharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $3.5M against a stock market value of $20.4M.
Distance to default 2.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 80.5%; Altman Z'' -634.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2024-12-26
Earliest Filing
2024-12-26
Latest Filing
partner: 2
licensee: 1
Counterparties (Filed by PVCT)
3 relationshipsCompanies named in PVCT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Provectus Biopharmaceuticals, Inc. | PVCT | partner | Assignor of rights under the License Agreement | 2024-12-26 | View |
| VisiRose, Inc. | — | partner | Assignee assuming duties and obligations under the License Agreement | 2024-12-26 | View |
| University of Miami | — | licensee | Original licensor of Patent Rights and Technology | 2024-12-26 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-01 | Officer/Director Change | View | |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-06-18 | Regulation FD; Exhibits | View | |
| 2026-04-21 | Other Events; Exhibits | View | |
| 2026-02-02 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-06-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-18 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-04-16 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-01-22 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2024-12-26 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2024-12-11 | Other Events; Financial Statements and Exhibits | View | |
| 2024-12-05 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-11-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-08-19 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-07-17 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2024-06-25 | Entry into Material Definitive Agreement; Amendments to Articles of Incorporation or Bylaws; Financi | Agreement | View |
| 2024-06-21 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-06-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-04-16 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-03-27 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR